Business Wire

CA-GALDERMA

28.2.2024 07:01:25 CET | Business Wire | Press release

Share
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio. Galderma’s extensive presence – including two late-breaking presentations on its first-in-class, investigational monoclonal antibody nemolizumab, five oral poster presentations, 16 e-posters, a symposium, and several ‘Meet the Expert’ and interactive booth sessions – highlights its commitment to listening to consumers, patients and healthcare professionals in order to deliver cutting-edge science and innovation that addresses their varied needs.

“Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action. We particularly look forward to presenting the latest updates from clinical trials of nemolizumab, which was recently accepted for filing by regulatory authorities in the U.S. and EU in prurigo nodularis and atopic dermatitis.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA

Data from across the full spectrum of dermatology to be presented
New data on nemolizumab, a first-in-class, investigational monoclonal antibody specifically designed to provide safe and rapid relief from itch, will be shared at AAD in two late-breaking presentations:

  • Results up to 52 weeks from an interim analysis of the OLYMPIA open-label extension study evaluating the long-term efficacy and safety of nemolizumab in patients with prurigo nodularis will be presented on Sunday, March 10, at 3:20 PM PST by Dr. Shawn Kwatra1
  • Results from an analysis of two pivotal phase III studies (ARCADIA 1 and ARCADIA 2) evaluating the efficacy and safety of maintenance treatment with nemolizumab at 48 weeks in patients with moderate to severe atopic dermatitis will be presented on Sunday, March 10, at 2:50 PM PST by Dr. Jonathan Silverberg2

Additionally, five oral posters will be presented on Friday, March 08, at the Upper Level, Sails Pavilion, Poster Center 1, including:

  • Results from the phase III READY-3 study evaluating the efficacy and safety of RelabotulinumtoxinA, our investigational novel, ready-to-use liquid neuromodulator, when used for combination treatment of frown lines (glabellar lines) and crow’s feet (lateral canthal lines) at 9:50 to 9:55 AM PST, presented by Dr. Joel Schlessinger3
  • Results from the phase IV LEAP and START studies, showing that trifarotene improves acne and related sequelae at 9:05 to 9:10 AM PST, and that it is efficacious and suitable for a broad range of patient types at 8:35 to 8:40 AM PST, both presented by Dr. Andrew Alexis4,5
  • Survey results on sensitive skin, including on dermatologists’ perspectives and educational exposures at 3:50 to 3:55 PM PST, presented by Dr. Sara Abdel Azim, and primary hyperhidrosis and sensitive skin syndrome at 10:10 to 10:15 AM PST, presented by Dr. Cleo Whiting6,7

Delving into patient and expert perspectives on itch
Our sponsored symposium, Perspectives on itch: Sharing experiences and understanding the burden, conducted in collaboration with the National Eczema Association, will bring together leading experts and patient representatives, Dr. Shawn Kwatra, Dr. Jonathan Silverberg, Dr. Matt Zirwas, and from the U.S. National Eczema Association, Wendy Begolka, to explore how dermatology providers can better recognize and address itch, one of the most burdensome and debilitating symptoms associated with diseases such as atopic dermatitis and prurigo nodularis. The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST.

More details on Galderma’s scientific presentations at AAD can be found here.
*All presenters are paid consultants or employees of Galderma.

About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

  1. Kwatra, S, et al. Nemolizumab long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: an interim analysis. Late-breaking abstract presented at AAD 2024.
  2. Silverberg, J, et al. Maintenance of efficacy and safety with nemolizumab at Week 48: results from two global phase III pivotal studies (ARCADIA 1 and ARCADIA 2) in patients with moderate-to-severe atopic dermatitis​. Late-breaking abstract presented at AAD 2024.
  3. Schlessinger, S, et al. Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA, when used for combination treatment of glabellar and lateral canthal lines. Oral poster presented at AAD 2024.
  4. Alexis, A, et al. Trifarotene shown to improve acne and related sequelae. Oral poster presented at AAD 2024.
  5. Alexis, A, et al. Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types. Oral poster presented at AAD 2024.
  6. Azim, SA, et al. Sensitive skin: a survey of dermatology resident physicians’ perspectives and educational exposures. Oral poster presented at AAD 2024.
  7. Whiting, C, et al. Primary hyperhidrosis and sensitive skin syndrome: a national pilot survey. Oral poster presented at AAD 2024.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240227061811/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 15:30:00 CET | Press release

The new SELYCE programme supports transition towards hybrid networks to strengthen Europe’s critical communications infrastructures SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial

From returns to restaurant bookings: Klarna’s AI assistant finds the best product & price, buys it for you, and you don’t pay until it arrives17.11.2026 15:26:00 CET | Press release

The Klarna AI-assistant takes the admin off your hands, on WhatsApp and iMessage. Waitlist opens today Klarna, the everyday finance network, today announced the Klarna AI-assistant, a personal assistant that handles shopping, returns, bookings, and everyday admin, so you don’t have to. Currently live with a small group of early users, the AI-assistant acts like a personal concierge, handling tasks on each customer’s behalf while keeping them firmly in control. Waitlist opens this week. The Klarna AI-assistant finds options and helps people decide, books anything from a table for two, to a babysitter, and keeps track of what they’re waiting for. It drafts email replies for approval, files receipts, and flags upcoming birthdays with gift ideas. This new AI-assistant builds on Klarna’s shopping assistant, a popular feature in its app. Klarna customers have spent more than $34 billion through the app’s built-in browser since 2020, a feature that lets you shop any website, including stores

Impartner Launches MCP Server to Connect AI Assistants with Live PRM Data17.11.2026 15:19:00 CET | Press release

Impartner MCP gives partner program teams conversational access to live partner pipeline, deal registration and account data through supported AI assistants, while maintaining existing user permissions and data access controls. Impartner, the world's leading partner revenue orchestration platform, today announced the launch of Impartner MCP, enabling organizations to connect AI assistants directly to live partner relationship management (PRM) data. Powered by the Model Context Protocol (MCP), an open standard for connecting AI assistants with external systems and data sources, the integration makes Impartner PRM information accessible within supported AI environments without requiring users to navigate multiple reports and dashboards. With Impartner MCP, teams can ask natural-language questions about partner pipelines, deal registrations, account activity and program performance, receiving answers grounded in real-time operational data and governed by their existing access permissions.

Incode Launches Incode Know Your Agent to Anchor AI Agent Trust in Verified Human Identity17.11.2026 15:14:00 CET | Press release

Businesses can now verify the human behind every AI agent acting on behalf of their customers and get access, control, and visibility over everything it does Incode, the identity platform trusted by more than 800 organizations, including nine of the top 10 US banks, eight of the top nine US telcos, and four of the top five global marketplaces, today launched Incode Know Your Agent, which ties every AI agent to a verified person and to the mandate that person set. With Incode Know Your Agent, businesses can get access, control, and visibility over every agent that acts on behalf of their customers. AI agents already act on behalf of people in banking, commerce, and everyday services. A fraudster’s agent can arrive with the same valid credentials as a customer’s, making it impossible for a business to tell them apart. AI agents are creating a new kind of economy, and fraud is growing inside it. Nearly seven in 10 Americans (69%) say they would let a bank’s AI assistant complete at least

Xsolla Launches Quest Builder and Backpack, Enabling Video Game Developers to Reward Players With Items to Collect, Own, and Give Away17.11.2026 15:00:00 CET | Press release

Xsolla Expands Its Core Platform With Xsolla Quest Builder and Backpack to Help Developers and Brands Use Digital Items to Attract and Retain Players Xsolla (USA), Inc., a global commerce company, today announced the launch of Xsolla Quest Builder, a no-code tool that lets video game developers reward players with digital items for reaching goals tracked through game events, alongside Xsolla Backpack, a persistent inventory where players keep those items. Xsolla Quest Builder helps developers acquire new users, improve retention and lifetime value, and learn what players value and want in their games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117128292/en/ Graphic: Xsolla Across the industry, players want more value from games and the digital items they acquire to enhance their in-game experience. To address this, along with rising user acquisition costs facing game developers, Xsolla is introducing a new way for pla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye